Availability
0
Your Basket is Empty
BR164345

Rimonabant - Bio-X

Cannabinoid receptor 1 (CB1) antagonist. Lowers consumption of food, via central and peripheral mechanisms. Reduces triglyceride and low-density lipoprotein levels (LDLs). Reduces nicotine dependence, potentially by modulating dopaminergic signalling. Serious adverse effects associated with Rimonabant include psychiatric disorders such as anxiety and depression.

Technical Data

CAS No: 168273-06-1
Synonyms: 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
Product Code: BR164345
MDL No: MFCD04034714
Chemical Formula: C22H21Cl3N4O
Molecular Weight: 463.79

References


  • Poirier B et al (2005). The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7(1):65-72.
  • Bifulco M et al (2007). Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 71(6):1445-56.
  • Padwal RS and Majumdar SR (2007). Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369(9555):71-7.

Solubility

Stability

Further Information


Datasheets


Rimonabant - Bio-X

CAS No:
168273-06-1
Synonyms:
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
MDL No:
MFCD04034714
Chemical Formula:
Molecular Weight:
463.79
Product Structure
References:
1. Poirier B et al (2005). The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7(1):65-72.
2. Bifulco M et al (2007). Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 71(6):1445-56.
3. Padwal RS and Majumdar SR (2007). Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369(9555):71-7.

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...